✦ Key Educational Takeaways
- Testosterone therapy typically suppresses menses (amenorrhea) within 3 to 6 months of initiating treatment.
- Testosterone is NOT contraception; pregnancy can occur even in individuals with complete amenorrhea on testosterone.
- Breakthrough spotting on testosterone can result from dose fluctuations, aromatization, missed injections, or atrophic changes.
- Gender-affirming menstrual healthcare emphasizes trauma-informed examinations and inclusive, destigmatizing clinical terminology.
Inclusive Reproductive Health: Transcending Gender Assumptions
Reproductive organs, hormonal cycles, and menstrual health are physiological functions, not gender identities. For transgender men, non-binary individuals, and gender-diverse people with a uterus, experiencing menstruation can often trigger intense gender dysphoria or psychological discomfort.
Understanding how gender-affirming hormone therapy (GAHT) interacts with ovarian and uterine physiology is foundational to dignified, evidence-informed healthcare.
How Testosterone Affects the Menstrual Cycle
For individuals assigned female at birth who initiate exogenous testosterone (via subcutaneous, intramuscular, or transdermal routes), elevated serum androgen levels exert negative feedback upon the pituitary gland. This suppresses pulsatile LH and FSH secretion, resulting in ovarian follicular quiescence and endometrial atrophy.
- Timeline to Amenorrhea: Menses cessation typically occurs within 3 to 6 months of therapeutic testosterone dosing. Initial cycles may become lighter, shorter, or unpredictably spaced before stopping completely.
- Breakthrough Spotting: Recurrence of bleeding after amenorrhea can occur due to fluctuations in serum trough levels, missed doses, peripheral aromatization of excess testosterone into estrogen, or benign vaginal atrophy. Non-androgenic options (such as progestin-only pills or levonorgestrel-releasing IUDs) can safely co-exist with testosterone to eliminate bleeding.
A Critical Clinical Clarification: Testosterone Is Not Birth Control
One of the most dangerous myths in queer healthcare is that testosterone acts as a reliable contraceptive. Even in individuals who have not menstruated for years while on testosterone, spontaneous anovulatory follicular escape and ovulation can occur. Testosterone is teratogenic to a developing fetus. Transmasculine individuals engaging in sexual intercourse with sperm-producing partners must utilize barrier methods or non-estrogenic contraception (such as progesterone implants, copper IUDs, or hormonal IUDs).
Seek medical evaluation if breakthrough vaginal bleeding occurs suddenly after more than a year of total testosterone amenorrhea, or if pelvic cramping is accompanied by abnormal discharge or urinary pain.
Authoritative Clinical & Educational References
- World Professional Association for Transgender Health (WPATH). Standards of Care for the Health of Transgender and Gender Diverse People, Version 8. Int J Transgend Health 2022;23(Suppl 1):S1-S259.
- Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2017;102(11):3869-3903.
- Arem H, Kobernik EK, Smith YR. The effect of gender-affirming testosterone therapy on the menstrual cycle: A systematic review. Am J Obstet Gynecol 2021;225(2):123-131.
Private Health & Cycle Calculators
HerCare calculators run 100% in-browser with client-side zero-storage architecture to safeguard your personal wellness data.